According to these PK analysis, TDM results on day 2 can be evaluable as a steady state in patients with a normal renal function

and mild renal dysfunction. Tanigawara et al. reported that ABK clearance was related to Ccr, age, and body weight. LEE011 concentration The volume of distribution was different in healthy subjects and infected patients, and this difference was more pronounced among disease types [13]. Ikeda et al. [14] reported that duration time of infusion, Ccr, body mass index (BMI), serum albumin level, and presence of chronic heart failure were significant factors influencing Cpeak. Based on these findings, frequent follow-up TDM is recommended for patients with severe infection, impaired renal function, obesity or underweight, concomitant use of nephrotoxic agents (aminoglycosides, amphotericin B, cyclosporine, contrast media, etc.), and particular clinical conditions which cause fluctuating volumes of distribution. In a nationwide questionnaire survey (203 institutions) concerning TDM of ABK, Cmax was used in 88 institutions, and Cmin was used in 79 institutions as the target serum

concentrations that indicate clinical efficacy [15]. Although previous reports mainly analyzed based on Cmax, recent studies used Cpeak as an indicator of clinical efficacy [4], [9], [10], [11], [12], [16] and [17]. Regarding the optimum administration method of ABK based on the PK-PD theory, it has been reported that the trough concentration (OR = 2.00) and patient’s age (OR = 1.06) were indices of the development selleck chemical of renal dysfunction on multiple logistic regression analysis. The mean

trough concentrations were 2.6 μg/mL in patients with developing nephrotoxicity and 0.5 μg/mL in patients without nephropathy [9]. Sato et al. described that incidences of nephrotoxicity were 2.5%, 5.2%, and 13.1% in patients with a trough value of 3-mercaptopyruvate sulfurtransferase 1 μg/mL, 2 μg/mL, and 5 μg/mL, respectively [4]. As for ototoxicity, Suzuki et al. demonstrated that there was no significant correlation between auditory brainstem response abnormality with either peak ABK concentration 20 μg/mL, trough concentration 4 μg/mL, or total dose100 mg/kg [18]. a. Clinical effect can be expected when the Cmax/MIC ratio was 8 or higher, and target Cpeak of 15–20 μg/mL is recommend (C1-III). In studies using Cmax as an indicator of clinical efficacy in patients with once daily administration at the approved dose of 150–200 mg, Kawano et al. [10] reported that the mean Cmax was 14.7 μg/mL, and the mean trough concentration was 0.74 μg/mL. Aikawa et al. [12] described that the mean Cmax and trough concentration were 16.2 and 1.1 μg/mL, respectively. Sato et al. [4] performed PK-PD analysis involving 174 patients with MRSA infection. On logistic regression analysis, the efficacy was high when Cmax was 7.9–12.5 μg/mL (OR = 6.7), and the incidences of nephrotoxicity were 2.5, 5.2, and 13.